The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2011The Sigma 1 Receptor as a Target for Disease-modifying Therapies in Parkinson's Disease
Objective/Rationale:
The Sigma-1 receptor (Sig-1R) is a protein involved in the transport of lipids and proteins between organelles within the cell. Impairment of these intracellular trafficking... -
Target Validation, 2011Validation of Dorsal Column Electrical Stimulation as a Target for Parkinson's Disease Therapy
Objective/Rationale:
Direct electrical stimulation of certain areas of the brain is an effective method to treat the motor symptoms of Parkinson’s, but it requires the insertion of electrodes into the... -
Target Validation, 2011Lamp-2a as a Therapeutic Target in Parkinson's Disease
Objective/Rationale:
Multiple pieces of evidence converge on the notion that accumulation of the protein alpha-synuclein is important for Parkinson’s disease (PD) pathogenesis. One of the ways through... -
Rapid Response Innovation Awards, 2011Direct Reprogramming of Cells into Dopamine Neurons
Objective/Rationale:
The availability of dopaminergic neurons for in-depth study or therapeutic replacement approaches has traditionally been limited. We aim to reprogram cells into dopaminergic... -
Rapid Response Innovation Awards, 2011Whole Exome Sequencing in an Amish Parkinson's Disease Pedigree
Objective/Rationale:
Although there is strong evidence to suggest genetics plays a role in Parkinson’s disease, the majority of the genes involved in Parkinson’s disease remain unidentified. We... -
LRRK2 Target Engagement Ligand, 2011Evaluating Novel Small Molecule Inhibitors of LRRK2 to Deliver PET Ligands
Objective/Rationale:
The exciting discovery of activating mutations in the LRRK2 kinase in familial PD patients, coupled with the emergence of kinase inhibitors as a new class of efficacious drugs...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.